Precautions and Warnings With Alogliptin
The type 2 diabetes drug alogliptin can increase your risk of pancreatitis and other problems, so make sure you are aware of the warnings and precautions before taking it. In addition, tell your healthcare provider if you have liver disease, kidney disease, or any allergies. If you are a woman, tell your healthcare provider if you are pregnant or nursing before using this drug.
- Liver disease, such as hepatitis, cirrhosis, or liver failure
- Kidney disease, such as kidney failure (renal failure)
- Had pancreatitis (inflammation of the pancreas)
- Gallstones (stones in your gallbladder)
- A history of alcoholism
- Any allergies, including to foods, dyes, or preservatives.
Also, let your healthcare provider know if you are:
- Pregnant or thinking of becoming pregnant
You should also tell your healthcare provider about all other medications you are taking, including prescription and nonprescription medicines, vitamins, and herbal supplements.
Some warnings and precautions to be aware of prior to taking this medication include the following:
- Very preliminary data suggests incretin mimetics, such as alogliptin, may increase the risk of precancerous cellular changes (called pancreatic duct metaplasia) in people with type 2 diabetes. Researchers are continuing to study the possibility that incretin mimetics might increase the risk of pancreatic cancer, although at this time there is not enough information to know for sure if there is any increased risk.
- Alogliptin may cause inflammation of the pancreas (known medically as pancreatitis). In some cases, pancreatitis can be severe enough to be life-threatening. Contact your healthcare provider right away if you have signs of pancreatitis, such as:
- Severe abdominal (stomach) pain, which may radiate to your back.
- Although generally rare, some people may have a severe allergic reaction to this medication. Stop taking alogliptin and contact your healthcare provider right away if you have signs of an allergic reaction to alogliptin, such as:
- An unexplained skin rash
- Itching, flaking, or peeling of the skin
- Difficulty breathing or swallowing
- Swelling of the face, lips, or throat.
- There have been reports of liver problems occurring in people treated with alogliptin. Your healthcare provider may want to test your liver function before starting treatment. Let him or her know if you develop any signs of liver problems, such as:
- Upper-right abdominal (stomach) pain
- Loss of appetite
- Fatigue or unusual tiredness
- Dark urine
- Yellowing of the skin or whites of the eyes (jaundice).
- Alogliptin is not likely to cause dangerously low blood sugar (hypoglycemia). However, if you take it in combination with other diabetes medicines that lower blood sugar, such as insulin or a sulfonylurea medicine, your risk for hypoglycemia may be higher.
- It is unknown whether this medication lowers the risk for coronary artery disease, strokes, or other heart and blood vessel problems associated with diabetes.
- Alogliptin may react with a few other medications (see Drug Interactions With Alogliptin).
- Alogliptin is a pregnancy Category B medication, which means it is probably safe for use during pregnancy, although the full risks are currently unknown. Talk to your healthcare provider before using this medication during pregnancy (see Nesina and Pregnancy).
- It is unknown whether alogliptin passes through breast milk. Therefore, if you are breastfeeding or plan to start, discuss this with your healthcare provider prior to taking the drug (see Nesina and Breastfeeding).